share_log

Doximity | 8-K: Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity | 8-K: Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity | 8-K：Doximity 公佈2025財年第二季度財務業績
美股SEC公告 ·  2024/11/08 05:12

Moomoo AI 已提取核心訊息

Doximity reported strong fiscal Q2 2025 results with revenue reaching $136.8 million, up 20% YoY, while net income grew 44% to $44.2 million. The company achieved an adjusted EBITDA of $76.1 million, representing a 41% YoY increase and margins of 55.7%. Operating cash flow surged 430% to $68.3 million.The company's clinical workflow tools saw record usage with over 600,000 unique active prescribers. Looking ahead, Doximity provided Q3 guidance with expected revenue between $152-153 million and adjusted EBITDA of $83-84 million. For fiscal year 2025, the company updated its guidance to revenue of $535-540 million and adjusted EBITDA of $274-279 million.As the leading digital platform for U.S. medical professionals, Doximity's network includes more than 80% of U.S. physicians across all specialties. The company continues to focus on helping doctors improve productivity and provide better patient care through its digital tools and collaboration platform.
Doximity reported strong fiscal Q2 2025 results with revenue reaching $136.8 million, up 20% YoY, while net income grew 44% to $44.2 million. The company achieved an adjusted EBITDA of $76.1 million, representing a 41% YoY increase and margins of 55.7%. Operating cash flow surged 430% to $68.3 million.The company's clinical workflow tools saw record usage with over 600,000 unique active prescribers. Looking ahead, Doximity provided Q3 guidance with expected revenue between $152-153 million and adjusted EBITDA of $83-84 million. For fiscal year 2025, the company updated its guidance to revenue of $535-540 million and adjusted EBITDA of $274-279 million.As the leading digital platform for U.S. medical professionals, Doximity's network includes more than 80% of U.S. physicians across all specialties. The company continues to focus on helping doctors improve productivity and provide better patient care through its digital tools and collaboration platform.
Doximity公佈了2025財年第二季度的強勁業績，營業收入達13680萬，同比增長20%，而凈利潤增長44%至4420萬。公司實現了調整後EBITDA爲7610萬，同比增加41%，利潤率爲55.7%。運營現金流激增430%至6830萬。公司的臨牀工作流程工具使用量創下歷史新高，活躍的處方醫生超過600,000名。展望未來，Doximity提供了第三季度的指導，預計營業收入在15200-15300萬之間，調整後EBITDA在8300-8400萬之間。對於2025財年，公司的指導更新爲營業收入在53500-54000萬之間，調整後EBITDA在27400-27900萬之間。作爲美國醫療專業人士領先的數字平台，Doximity的網絡覆蓋了超過80%的美國各科醫生。公司繼續致力於幫助醫生提高生產力，並通過其數字工具和協作平台提供更好的患者護理。
Doximity公佈了2025財年第二季度的強勁業績，營業收入達13680萬，同比增長20%，而凈利潤增長44%至4420萬。公司實現了調整後EBITDA爲7610萬，同比增加41%，利潤率爲55.7%。運營現金流激增430%至6830萬。公司的臨牀工作流程工具使用量創下歷史新高，活躍的處方醫生超過600,000名。展望未來，Doximity提供了第三季度的指導，預計營業收入在15200-15300萬之間，調整後EBITDA在8300-8400萬之間。對於2025財年，公司的指導更新爲營業收入在53500-54000萬之間，調整後EBITDA在27400-27900萬之間。作爲美國醫療專業人士領先的數字平台，Doximity的網絡覆蓋了超過80%的美國各科醫生。公司繼續致力於幫助醫生提高生產力，並通過其數字工具和協作平台提供更好的患者護理。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    iCoreConnect
    ICCT
    -- 2.240
    VSee Health
    VSEE
    -- 1.200
    SHL Telemedicine
    SHLT
    -- 2.073
    眾巢醫學
    ZCMD
    -- 1.280
    HeartBeam
    BEAT
    -- 2.010
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點